Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on oncology therapies, with a market capitalization of US$32.9 million. The company faces significant risks including negative shareholder equity, substantial share dilution, and volatile share price, but has seen some narrowing of net losses and revenue growth in recent earnings reports. Apollomics continues clinical development of vebreltinib and uproleselan, with recent updates on trial results, funding, and board changes.
FOSTER CITY, Calif., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( "Apollomics" or the "Company" ) ( Nasdaq: APLM ) announced today entering into a settlement agreement ( the "Settlement Agreement" or the "Agreement" ) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group ...
FOSTER CITY, Calif., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( Nasdaq: APLM ) ( "Apollomics" or the "Company" ) , a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors ( "Board" ) ...
